Bibliografía del artículo
1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994.
2. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46:986-93, 2005.
3. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-35, 2001.
4. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 120:311-21, 2007.
5. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83:148-58, 2005.
6. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 147:293-300, 2004.
7. Alexander JH, Harrington RA, Tuttle RH, Berdan LG, Lincoff AM, Deckers JW et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 83:1147-51, 1999.
8. Antman EM, Cohen M, Bernink PJLM, McCabe CH, Horacek T, Papuchis G et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 284:835-42, 2000.
9. Cipollone F, Ciabattoni G, Patrignani P, Pasquale M, Di Gregorio D, Bucciarelli T et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 102:1007-13, 2000.
10. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115:2490-96, 2007.
11. Mortensen J, Poulsen TS, Grove EL, Refsgaard J, Nielsen HL, Pedersen SB et al. Monitoring aspirin therapy with the platelet function analyser-100. Scand J Clin Lab Invest 68:786-92, 2008.
12. Muir AR, Patterson C, McMullin MF, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart 95:1225-9, 2009.
13. Blais N, Pharand C, Lordkipanidze M, Sia YK, Merhi Y, Diodati JG. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG), and urinary 11-dehydrothromboxane B2. Thromb Haemost 102:404-11, 2009.
14. Akay OM, Canturk Z, Akin E, Bal C, Gulbas Z. Aspirin resistance frequency: a prospective study in 280 healthy Turkish volunteers. Clin Appl Thromb Hemost 15:98-102, 2009.
15. Madsen EH, Schmidt EB, Maurer-Spurej E, Kristensen SR. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100. Platelets 19:335-41, 2008.
16. Nielsen HL, Kristensen SD, Thygesen SS, Mortensen J, Pedersen SB, Grove EL et al. Aspirin response evaluated by the VerifyNow aspirin system and light transmission aggregometry. Thromb Res 123:267-73, 2008.
17. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thromboelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 49:1705-9, 2005.